pharmaLevers GmbH in Liquidation is a Swiss life sciences consulting firm focused on Market Access — namely pricing and reimbursement for pharmaceuticals and medical devices, health economics, HTA, and policy analysis. The main content clearly states that the company was founded in 2011 by Kurt R. Müller; it also explicitly notes that the company is “currently in liquidation under Swiss law and no longer engages in active business activities,” which is the most important factor when evaluating it.
Based on the content, this is not a SaaS or enterprise software product, but a professional consulting services website. Its core services include value assessment, aligning value perception, improving payer acceptance, pricing and reimbursement strategies for innovative therapies, as well as Pricing & Reimbursement, Strategic Pricing, Managed Entry Agreements, Payer Marketing, Stakeholder Management, HTA Lever, and Health Economy. Its methodology emphasizes understanding payer assessment criteria, adapting local value dossiers, handling pricing arguments, analyzing P&R policies, evaluating DRG and coding issues, and covering highly complex areas such as cell and gene therapy, precision medicine, digital health, and medical devices.
The official website does not provide plans, quotes, payment methods, a free version, or trial information. It also does not show typical SaaS capabilities such as user accounts, team permissions, workflows, dashboards, third-party integrations, APIs, developer documentation, or self-hosted deployment. The website terms only state that the site uses SSL/HTTPS encryption, is governed by Swiss law, and that its content does not constitute an offer.
Its strengths are its highly specialized positioning and the founder’s background across R&D, medical devices, payers, generics, policy, and consulting. The site also includes topical content on affordability, OECD data, budget impact for cell/gene therapies, and Managed Entry Agreements. The drawbacks are equally clear: the company is in liquidation and no longer actively operating; there is no information indicating a productized software offering; and it is not possible to verify the delivery team, service support, pricing, or procurement process.
As a public reference source, it may be useful for market access, pricing and reimbursement, and policy research professionals at pharmaceutical companies, biotech firms, and medical device companies who want to read its methodological content. However, if you are looking to purchase services or a system, its current status makes it unsuitable as a first-choice vendor. The main content does not provide information on access from China, and payment methods are unknown. Users in China should prioritize local or international market access consultancies, pharmaceutical data providers, and real-world evidence platforms that are still actively operating.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on pharmalevers.com official site.
pharmalevers.com is an Germany SaaS Tools provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach pharmalevers.com directly.